XEN gel stent: The solution designed by AqueSys®

Abstract

XEN Gel Stent is the solution developed by AqueSys, Inc. by merging together the best of both worlds: a long time proven outflow mechanism of action at the subconjunctival space with a minimally invasive approach creating Minimally Invasive Maximum Efficacy technology (MIME). A detailed explanation of the rationale and calculations are given to allow the reader to get a complete comprehension of the science behind the XEN Gel Stent. The surgical technique is summarized in 10 simple steps with images and videos from real surgery and animations. Results from international studies showed a reduction of 38 % of the mean IOP at 24 months and a reduction of 48 % of medications at 24 months from best medicated IOP. One hundred and eighteen patients were enrolled in the study with a mean preoperative IOP of 23 mmHg (non-washed-out IOP value). At postoperative, the mean IOPs were 15.4 at 12 months, 14.5 at 18 months, and 14.3 at 24 months. The mean decrease in IOP (mmHg) was -7.6 (-33 % reduction) at 12 months and -8.5 (-37 % reduction) at 18 months from best medicated IOP.